Sermorelin for Sale: What One Lot Number Lets You Check

Sermorelin for sale is a phrase attached to two very different objects: a lyophilised research vial bought at checkout, and a compounded prescription filled by a pharmacy. This page is about the first, and specifically about which of its claims survive contact with a document.

A listing is a set of assertions. Most of them are not testable by a reader: nobody can audit a warehouse from a browser. One field changes that, because it points at a laboratory report on a defined quantity of material. That field is the lot number, and the worked example below is lot 38-01260229.

Sermorelin for sale: the fields that make a listing checkable

The useful distinction is not between a good seller and a bad one. It is between a claim that can be failed and a claim that cannot. “Pharmaceutical grade” cannot be failed, because no agency issues that grade and no test reports it. “99.79 percent by HPLC-UV-MS on lot 38-01260229” can be failed, because it names a method, a number and the material it applies to.

The table sets out the fields worth looking for, what a checkable listing puts in each, and what this particular listing puts there.

Row five is the one most readers skip. A test scope is a list, and the informative part of a list is what is missing from it. The same logic applied across a whole market, with the criteria weighted, is the subject of our scored source comparison.

Three checks the certificate lets you run in a minute

The first check is identity by sequence. The certificate prints the amino acid sequence in three-letter code. Converted to single-letter code it reads YADAIFTNSYRKVLGQLSARKLLQDIMSR, twenty-nine residues, with a C-terminal amide. That is the canonical GHRH(1-29) amide sequence. The document therefore describes sermorelin and not an adjacent growth hormone secretagogue with a similar marketing story.

The second check is identity by mass. PubChem CID 16132413 returns the title Sermorelin, molecular formula C149H246N44O42S and a molecular weight of 3357.9. Those three values match the vendor’s own product description exactly. Two independent descriptions of the same molecule agreeing is a weak check on its own and a useful one in combination with the first, because a mismatched formula would end the enquiry immediately.

The third check is arithmetic on the quantity result. The certificate reports 11.31 mg against a 10 mg label, which is 13.1 percent above label on this batch. A vendor that publishes a quantity result is publishing a number that could have embarrassed it, which is a different posture from publishing purity alone. What that figure is not is a property of the product: it describes what this lot assayed on one date.

The two lines this lot’s certificate does not carry

There is no bacterial endotoxin result on it and no sterility screen. The document reports purity and quantity, and it does so competently, with the laboratory address in Tucson, an analysis date of 7 February 2026, a signature date six days later and a named analyst. It is a narrow document rather than a weak one.

The gap matters because of what buyers do with a lyophilised powder. Material intended for a parenteral route is assessed for pyrogens as a matter of course under FDA’s endotoxin testing guidance, and purity by chromatography does not address that question at any percentage. FDA’s own stated concern about growth hormone secretagogue peptides in general is the risk of immunogenicity arising from aggregation and peptide-related impurities, which is precisely the class of question a microbiological panel answers and a purity figure does not.

Two framings of that fact are available and only one is accurate. Saying that the vendor does not test for endotoxin is a claim about a company, and we have no evidence for it. Saying that the certificate for lot 38-01260229 covers purity and quantity is a claim about a document, and it is exactly what the document shows. Testing scope is a batch property, and we apply that rule to every certificate we read.

The claims a seller of this material cannot make

Sermorelin has an unusual regulatory history for a compound sold this way. It was a real approved drug. EMD Serono held two applications under the name Geref: NDA 019863, the pituitary diagnostic, with submissions from May 1991, and NDA 020443, the therapeutic product, approved 26 September 1997. Both are now discontinued and there is no US label: DailyMed returns no labelling for the substance. FDA’s product record carries the Federal Register determination that the products were not removed from sale for reasons of safety or effectiveness.

That history does not transfer to a vial bought online. An approval attaches to a specific product made under a specific process by a specific applicant. The material in a research listing was made by somebody else, under a process no regulator has reviewed, and the discontinued approval says nothing about it. A listing that leans on the Geref history to imply that its own powder is approved is making a claim the history does not support.

The approved indications are worth naming for the same reason: pituitary diagnostics and growth hormone deficiency in children. That is the evidence base. PubMed returns 332 papers mentioning sermorelin and only three with it in the title, and a search for sermorelin together with anti-aging returns nothing at all. The background to that literature is set out in our research record on the compound.

What the assay does to the price

The listing runs at $99.99, sells at $72.00, and falls to $36.00 with the code. On the printed 10 mg that is $3.60 per milligram. On the 11.31 mg the certificate reports for this lot it is $3.18. Buying three, five or ten vials reduces the list price by 3, 5 or 10 percent as a separate mechanism, and $250 is where carriage becomes free.

The point of running both figures is not that the cheaper one is the true one. It is that a per-milligram comparison between two sellers is meaningless unless both are dividing by the same kind of number. A seller who publishes only a label mass is quoting the first figure. A seller who publishes a quantity result is quoting something you can recompute. The full arithmetic, including what the quantity tiers do and do not stack with, is in the price breakdown.

What no listing on this market can show you

A certificate describes a powder. It does not describe an effect, and the gap between the two is where most of the marketing in this category sits. The clinic market sells sermorelin for adult vitality, sleep and body composition. The literature that exists covers paediatric growth hormone deficiency and pituitary function testing, which is a different subject.

The search itself is worth running once, because the result is counterintuitive. ClinicalTrials.gov returns dozens of studies for a sermorelin query and none of them name sermorelin as an intervention: they are trials of growth hormone-releasing hormone, tesamorelin and octreotide, surfaced by the registry’s synonym matching. Sermorelin is GHRH(1-29), so parts of the GHRH literature are genuinely relevant to it, but a GHRH trial is not a sermorelin trial and citing one as though it were is the most common error on pages in this category.

The compound it is most often confused with is the one that did keep its approval. Tesamorelin is a stabilised GHRH analog with a current marketing authorisation, and it is a different purchase in every respect that matters. Ipamorelin and MK-677, which are sold alongside sermorelin as though they were interchangeable, act at the ghrelin receptor instead. Confirming which of the four is actually in a vial comes back to the sequence and the mass, which is where this page started.